Aduro Biotech just signed a $750MM ($200MM of which was up-front) deal with Novartis for the development of modulators of the STING pathway to enhance the immunogenicity of cancer cells. Continue reading
![](https://blogs.shu.edu/cancer/files/2014/07/cancerBiology180x110.jpg)
Aduro Biotech just signed a $750MM ($200MM of which was up-front) deal with Novartis for the development of modulators of the STING pathway to enhance the immunogenicity of cancer cells. Continue reading